Abstract:Introduction: The intricate interplay between gut microbiota and hyperuricemia remains a subject of growing interest. However, existing studies only provided snapshots of the gut microbiome at single time points, the temporal dynamics of gut microbiota alterations during hyperuricemia progression and the intricate interplay between the gut barrier and microbiota remain underexplored. Our investigation revealed compelling insights into the dynamic changes in both gut microbiota and intestinal barrier function throughout the course of hyperuricemia. Methods: The hyperuricemia mice (HY) were given intragastric administration of adenine and potassium oxalate. Gut microbiota was analyzed by 16S rRNA sequencing at 3, 7, 14, and 21 days after the start of the modeling process. Intestinal permeability as well as LPS, TNF-α, and IL-1β levels were measured at 3, 7, 14, and 21 days. Results: We discovered that shifts in microbial community composition occur prior to the onset of hyperuricemia, key bacterial Bacteroidaceae, Bacteroides, and Blautia exhibited reduced levels, potentially fueling microbial dysbiosis as the disease progresses. During the course of hyperuricemia, the dynamic fluctuations in both uric acid levels and intestinal barrier function was accompanied with the depletion of key beneficial bacteria, including Prevotellaceae, Muribaculum, Parabacteroides, Akkermansia, and Bacteroides, and coincided with an increase in pathogenic bacteria such as Oscillibacter and Ruminiclostridium. This microbial community shift likely contributed to elevated lipopolysaccharide (LPS) and pro-inflammatory cytokine levels, ultimately promoting metabolic inflammation. The decline of Burkholderiaceae and Parasutterella was inversely related to uric acid levels, Conversely, key families Ruminococcaceae, Family_XIII, genera Anaeroplasma exhibited positive correlations with uric acid levels. Akkermansiaceae and Bacteroidaceae demonstrating negative correlations, while LPS-containing microbiota such as Desulfovibrio and Enterorhabdus exhibited positive correlations with intestinal permeability. Conclusion: In summary, this study offers a dynamic perspective on the complex interplay between gut microbiota, uric acid levels, and intestinal barrier function during hyperuricemia progression. Our study suggested that Ruminiclostridium, Bacteroides, Akkermansiaceae, Bilophila, Burkholderiaceae and Parasutterella were the key bacteria that play vital rols in the progress of hyperuricemia and compromised intestinal barrier, which provide a potential avenue for therapeutic interventions in hyperuricemia.

Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout

The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Gut microbiota plays a significant role in gout

The role of gut microbiota in gout: Is gut microbiota a potential target for gout treatment

Research Progress in the Regulation of Gut Microbiota on Diet-Induced Hyperuricemia

Changes in Gut Microbiota Structure and Function in Gout Patients

Antibiotic-induced gut microbiota dysbiosis has a functional impact on purine metabolism

Gut microecology: effective targets for natural products to modulate uric acid metabolism

The Interaction Between Dietary Fructose and Gut Microbiota in Hyperuricemia and Gout

Metagenomic Study Revealed the Potential Role of the Gut Microbiome in Gout

Alteration of Gut Microbiome and Correlated Amino Acid Metabolism Contribute to Hyperuricemia and Th17-Driven Inflammation in Uox-KO Mice

The potential of probiotics in the amelioration of hyperuricemia

Probiotics, bioactive compounds and dietary patterns for the effective management of hyperuricemia: a review

Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions

Metagenomic analysis revealed the potential role of gut microbiome in gout

A dynamics association study of gut barrier and microbiota in hyperuricemia

Integrated Microbiome and Metabolome Analysis Reveals the Key Role of Taurohyocholate in the Treatment of Hyperuricemia with Lacticaseibacillus Rhamnosus 2016SWU.05.0601

ADVANCEMENTS IN UNDERSTANDING THE MOLECULAR MECHANISMS REGULATING URIC ACID METABOLISM IN THE INTESTINE

Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development

Hyperuricemia and its related diseases: mechanisms and advances in therapy